rc 3095 has been researched along with interleukin-8 in 1 studies
| Studies (rc 3095) | Trials (rc 3095) | Recent Studies (post-2010) (rc 3095) | Studies (interleukin-8) | Trials (interleukin-8) | Recent Studies (post-2010) (interleukin-8) |
|---|---|---|---|---|---|
| 108 | 2 | 26 | 23,523 | 1,167 | 9,990 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarenga, DM; Antunes, MM; Bonorino, C; Czepielewski, RS; da Silva, RD; da Silva, VD; Jaeger, N; Lopes, TG; Marques, PE; Menezes, GB; Pereira, RV; Porto, BN; Rigo, MM | 1 |
1 other study(ies) available for rc 3095 and interleukin-8
| Article | Year |
|---|---|
GRPR antagonist protects from drug-induced liver injury by impairing neutrophil chemotaxis and motility.
Topics: Animals; Bombesin; Cell Movement; Cells, Cultured; Chemical and Drug Induced Liver Injury; Chemotaxis; Humans; Interleukin-8; Mice; Mice, Inbred Strains; Neutrophil Activation; Neutrophils; Peptide Fragments; Protein Binding; Receptors, Bombesin; Receptors, Interleukin-8B; Signal Transduction | 2017 |